跳转至内容
Merck

I0060000

异环磷酰胺

European Pharmacopoeia (EP) Reference Standard

别名:

Ifex, N,3-双(2-氯乙基)四氢-2H-1,3,2-氧杂磷烷基-2-胺-2-氧化物

登录查看公司和协议定价

选择尺寸

50 MG
$225.00

$225.00


请联系客服了解存货情况

获取大包装报价

选择尺寸

变更视图
50 MG
$225.00

About This Item

经验公式(希尔记法):
C7H15Cl2N2O2P
CAS号:
分子量:
261.09
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24

$225.00


请联系客服了解存货情况

获取大包装报价

等级

pharmaceutical primary standard

API类

ifosfamide

制造商/商品名称

EDQM

技术

HPLC: suitable
gas chromatography (GC): suitable

应用

pharmaceutical (small molecule)

包装形式

neat

储存温度

2-8°C

SMILES字符串

ClCCNP1(=O)OCCCN1CCCl

InChI

1S/C7H15Cl2N2O2P/c8-2-4-10-14(12)11(6-3-9)5-1-7-13-14/h1-7H2,(H,10,12)

InChI key

HOMGKSMUEGBAAB-UHFFFAOYSA-N

正在寻找类似产品? 访问 产品对比指南

一般描述

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

应用

Ifosfamide EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

生化/生理作用

异环磷酰胺是一种氮芥类化合物,是环磷酰胺的结构异构体。 异环磷酰胺是一种前药,必须通过细胞色素P450转化为生物活性成分。 它在癌症化疗中可用作抗肿瘤药,但是异环磷酰胺比环磷酰胺更可能引起肾毒性。

包装

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他说明

Sales restrictions may apply.

象形图

Skull and crossbonesHealth hazard

警示用语:

Danger

危险分类

Acute Tox. 3 Oral - Carc. 1B - Eye Irrit. 2 - Muta. 1B - Repr. 1B

储存分类代码

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Metin Tascilar et al.
The oncologist, 12(11), 1351-1360 (2007-12-07)
The treatment outcome of patients with locally advanced and metastatic soft tissue sarcomas is poor. Doxorubicin is regarded as standard treatment, but its use is featured by the occurrence of cardiotoxicity. This hinders the administration of this drug at high
Priti N Patel
The Annals of pharmacotherapy, 40(2), 299-303 (2006-01-05)
To evaluate the use of methylene blue for the treatment of ifosfamide-induced encephalopathy. MEDLINE (1966-August 2005) and International Pharmaceutical Abstracts (1971-August 2005) were searched using the terms methylene blue, ifosfamide, encephalopathy, and neurotoxicity. Several case reports and one retrospective chart
T Ajithkumar et al.
Clinical oncology (Royal College of Radiologists (Great Britain)), 19(2), 108-114 (2007-03-16)
Encephalopathy is a potentially fatal toxicity of ifosfamide. Clinical manifestations of encephalopathy range from fatigue and confusion to coma and death. Early identification of this toxicity and prompt cessation of ifosfamide are the essential elements in the management of ifosfamide
Jean-Yves Blay et al.
European journal of cancer (Oxford, England : 1990), 50(6), 1137-1147 (2014-02-12)
This randomised phase III trial evaluated first-line trabectedin versus doxorubicin-based chemotherapy (DXCT) in patients with advanced/metastatic translocation-related sarcomas (TRS). Patients were randomly assigned (1:1) to receive trabectedin 1.5mg/m2 24-h intravenous (i.v.) infusion every 3 weeks (q3wk) (Arm A), or doxorubicin
Renée L Mulder et al.
The Cochrane database of systematic reviews, (2)(2), CD006300-CD006300 (2010-02-19)
Alkylating agents, such as cyclophosphamide and ifosfamide, play a major role in the improved survival of children and young adults with bone and soft tissue sarcoma. However, there is still controversy as to their comparative anti-tumour efficacy and possible adverse

Questions

Reviews

No rating value

Active Filters

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持